Cord Blood America, Inc. (OTCBB: CBAI)

Cord Blood America, Inc. (OTCBB: CBAI)

Cord Blood America, through its wholly owned subsidiary CorCell Companies, Inc., is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. For an initial fee of $2,075 and an annual storage fee of approx. $125 for each year thereafter, CorCell provides the following services to each customer: Collection; Full-Time Physician and Customer Support; Transportation; Comprehensive Testing; and Cord Blood Preservation. At present, all of CorCells cord blood units are tested, processed and stored at Progenitor Cell Therapies in Hackensack, NJ.

There is uniformity in the belief that stem cells will play a key role in fighting disease as we move forward through this century. Some scientists are confident that stem cells will launch a new era in medicine, perhaps even curing some of our most intractable diseases. The umbilical cord which, at birth, traditionally has been thrown away, contains a rich store of stem cells. Cord Blood America, Inc., through its wholly owned subsidiaries, CorCell Companies Inc., and Cord Partners, Inc., markets a service to preserve the umbilical cord blood in a patented process for future use exclusively by the donating family. The collection takes less than five minutes, is painless, easy and non-invasive. Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders and immune deficiencies. This list is guaranteed to grow as medical research learns more about the incredible healing power of stem cells.

Corporate Strategy

What Cord Blood America offers is the proverbial once in a lifetime opportunity. You cannot give birth to the same child twice. That is why marketing and education are such important factors in this sector. Cord Blood America has assembled an experienced marketing team second to none in the industry. CBAI has nurtured deep relationships with healthcare insurance providers in key cities to drive the message to the parents when the insurance company is notified of their pregnancy.

This is a growth industry: Only a few years ago, five percent of the four million women in the U.S. giving birth knew about preserving their umbilical cord blood and two percent of these took advantage of this life-saving procedure. The number of cord blood samples stored has since been growing by 50 percent a year, and more than four percent of all those giving birth now preserve the umbilical cord. Cord Blood America intends to be number one in educating about the advantages of these cord blood banking services and then to be the top performer in signing new families to utilize its services. The Company already had revenues topping $4.2 million in 2008.

Learn More.

Download and Read Our Investor Guide.

Company History

• January 2003 - Cord Blood Americas original stem cell storage company, Cord Partners, Inc., launched
• January 2005 - Cord Partners reverse merged into Cord Blood America, Inc. (CBAI), commenced trading on the OTCBB
• January 2006 - CBAI purchases assets of Cryobanks for Oncologic and Reproductive Donors (C.O.R.D.)
• October 2006 - CBAI purchases Corcell Operations changes name to CorCell Companies, Inc.
• March 2007 - CBAI purchases assets of CorCell - changes name to CorCell, Ltd.
• August 2007 - CBAI purchases assets of CureSource, Inc.
• January 2009 - CBAI launches social media communications.
May 2009 - CBAI begins building state of the art laboratory.